Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #281726 on Anavex Life Sciences Corp (AVXL)
georgejjl
11/07/20 10:51 PM
#281727 RE: Turner2017 #281726
The ANAVEX®2-73 (blarcamesine) U.S. Phase 2 study enrolled 31 patients with Rett syndrome and all patients completed the 7-week trial.
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial
ExtremelyBullishZig
11/07/20 11:46 PM
#281731 RE: Turner2017 #281726